•The correlation between log( α3) and log(β 3) was assumed to be 0 (assuming independence of log(α3) and log( β3)). With this prior, the clinical trial data below ( Table 4.1.3-1 ), including: •Phase 3 study of ipilimumab administered at 3 mg/kg vs 10 mg/kg (Study CA184169, N=360 per arm) Revised Protocol No.: 04 Date: 31-May-2019 217 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS •Phase 2 study of multiple doses of ipilimu mab monotherapy (Study CA184022, N=71 per arm) •Phase 3 study in HLA-A*0201 positive particip ants (Study MDX010- 20, ipilimumab 3 mg/kg monotherapy arm with N=131) •Data from other various Phase 2 studies (N= 111 for pooled 3 mg/kg; N=325 for pooled 10 mg/kg, from Clinical Overview of a Common Technical Document for ipilimumab) were used to generate the posterior for ipilimumab. The generation of the posterior uses the meta- analytic predictive approach, such that heterogeneity between the historical study and the current study was incorporated, by defining between-trial standard deviations τ1 and τ 2 for log( α3) and log(β3), respectively.